Optimal therapy in Gaucher disease

por Goker-Alpan, Ozlem
Publicado 2010

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease

por Limgala, Renuka P., Goker-Alpan, Ozlem
Publicado 2020

Gaucher Disease and the Synucleinopathies

por Hruska, Kathleen S., Goker-Alpan, Ozlem, Sidransky, Ellen
Publicado 2006

Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases

por Ivanova, Margarita M., Changsila, Erk, Iaonou, Chidima, Goker-Alpan, Ozlem
Publicado 2019

The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease

por Limgala, Renuka P., Fikry, Jaqueline, Veligatla, Vasudha, Goker-Alpan, Ozlem
Publicado 2020

TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease

por Ivanova, Margarita, Dao, Julia, Noll, Lauren, Fikry, Jacqueline, Goker-Alpan, Ozlem
Publicado 2021

Circulated TGF-β1 and VEGF-A as Biomarkers for Fabry Disease-Associated Cardiomyopathy

por Ivanova, Margarita M., Dao, Julia, Slayeh, Omar Abu, Friedman, Andrew, Goker-Alpan, Ozlem
Publicado 2023

Rapid Clathrin-Mediated Uptake of Recombinant α-Gal-A to Lysosome Activates Autophagy

por Ivanova, Margarita M., Dao, Julia, Kasaci, Neil, Adewale, Benjamin, Fikry, Jacqueline, Goker-Alpan, Ozlem
Publicado 2020

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease

por Ivanova, Margarita M., Dao, Julia, Kasaci, Neil, Friedman, Andrew, Noll, Lauren, Goker-Alpan, Ozlem
Publicado 2022

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability

por Pastores, Gregory M., Rosenbloom, Barry, Weinreb, Neal, Goker-Alpan, Ozlem, Grabowski, Gregory, Cohn, Gabriel M., Zahrieh, David
Publicado 2014

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey

por Schwartz, Ida Vanessa D., Göker-Alpan, Özlem, Kishnani, Priya S., Zimran, Ari, Renault, Lydie, Panahloo, Zoya, Deegan, Patrick
Publicado 2017

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy

por Goker-Alpan, Ozlem, Longo, Nicola, McDonald, Marie, Shankar, Suma P, Schiffmann, Raphael, Chang, Peter, Shen, Yinghua, Pano, Arian
Publicado 2016

Biofabrication of an in-vitro bone model for Gaucher disease

por Banerjee, Dishary, Ivanova, Margarita M, Celik, Nazmiye, Kim, Myoung Hwan, Derman, Irem Deniz, Limgala, Renuka Pudi, Ozbolat, Ibrahim T, Goker-Alpan, Ozlem
Publicado 2023

Pregnancy Outcomes in Late Onset Pompe Disease

por Goker-Alpan, Ozlem, Kasturi, Vellore G., Sohi, Maninder K., Limgala, Renuka P., Austin, Stephanie L., Jennelle, Tabitha, Banikazemi, Maryam, Kishnani, Priya S.
Publicado 2020

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease

por Ivanova, Margarita M., Dao, Julia, Kasaci, Neil, Adewale, Benjamin, Nazari, Shaista, Noll, Lauren, Fikry, Jacqueline, Sanati, Armaghan Hafez, Goker-Alpan, Ozlem
Publicado 2021

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease

por Limgala, Renuka Pudi, Ioanou, Chidima, Plassmeyer, Matthew, Ryherd, Mark, Kozhaya, Lina, Austin, Lauren, Abidoglu, Cem, Unutmaz, Derya, Alpan, Oral, Goker-Alpan, Ozlem
Publicado 2016

Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants

por Limgala, Renuka Pudi, Furtak, Vyacheslav, Ivanova, Margarita M., Changsila, Erk, Wilks, Floyd, Fidelia‐Lambert, Marie N., Goker‐Alpan, Ozlem, Gondré‐Lewis, Marjorie C.
Publicado 2021

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies...

por Hughes, Derralynn A., Deegan, Patrick, Giraldo, Pilar, Göker-Alpan, Özlem, Lau, Heather, Lukina, Elena, Revel-Vilk, Shoshana, Scarpa, Maurizio, Botha, Jaco, Gadir, Noga, Zimran, Ari
Publicado 2023

Clinical course and prognosis in patients with Gaucher disease and parkinsonism

por Lopez, Grisel, Kim, Jenny, Wiggs, Edythe, Cintron, Dahima, Groden, Catherine, Tayebi, Nahid, Mistry, Pramod K., Pastores, Gregory M., Zimran, Ari, Goker-Alpan, Ozlem, Sidransky, Ellen
Publicado 2016

Gaucher Disease in Bone: From Pathophysiology to Practice

por Hughes, Derralynn, Mikosch, Peter, Belmatoug, Nadia, Carubbi, Francesca, Cox, TimothyM, Goker‐Alpan, Ozlem, Kindmark, Andreas, Mistry, PramodK, Poll, Ludger, Weinreb, Neal, Deegan, Patrick
Publicado 2019